News | April 25, 2022
Global AYUSH meet ends with promise of Rs 9000 cr. in investment
Investment and innovation opportunities in the field of AYUSH are limitless : Sarbananda Sonowal
Investment and innovation opportunities in the field of AYUSH are limitless : Sarbananda Sonowal
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
Subscribe To Our Newsletter & Stay Updated
